SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Part of paid clinical trials in Tampa, Florida.

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Study ID
NCT03614949
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Stereotactic body radiation therapy (SBRT) — RADIATION
    SBRT with 24 Gy in 3 fractions to participants with ≥ 2 metastatic sites.
  • Atezolizumab — DRUG
    Atezolizumab 1200 mg intravenously (IV) every 3 weeks.

Study Details

The purpose of this study is to see if treatment with atezolizumab and stereotactic body radiation therapy (SBRT) will improve the objective response rate (ORR) compared with atezolizumab alone in patients with recurrent, persistent, or metastatic cervical cancer.

Key Dates

Start date
Jan 29, 2019
Status verified
Mar 2026
Primary completion
Oct 31, 2028
Completion
Oct 31, 2028

Study Design

Enrollment
21 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Combination Therapy
    Stereotactic body radiation therapy (SBRT) followed by atezolizumab, 1 week later.

Primary Outcome Measure

Overall Response Rate (ORR) [ Time Frame: Up to 5 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
H. Lee Moffitt Cancer Center and Research InstituteTampaFlorida33612-
Ohio State University - OSUMC - Wexner Medical CenterHilliardOhio43026-

Find similar trials in Tampa, FL

By condition
Cervical cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
H. Lee Moffitt Cancer Center and Research Institute· Tampa, FLOhio State University - OSUMC - Wexner Medical Center· Hilliard, OH

Related Studies